Trinity Biotech Given 180 Days to Meet Nasdaq Listing Standards on Share Value

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Trinity Biotech received a Nasdaq non-compliance notice for failing to maintain minimum share value requirements. The company has 180 days to restore compliance or face delisting.

Trinity Biotech Given 180 Days to Meet Nasdaq Listing Standards on Share Value

Trinity Biotech plc received a non-compliance notice from Nasdaq on February 19, 2026, after failing to maintain the minimum market value of publicly held shares (MVPHS) required under listing standards. The company's MVPHS fell below the $15 million threshold mandated by Nasdaq Listing Rule 5450(b), triggering the regulatory notification.

The Irish diagnostics company has until August 18, 2026—a period of 180 calendar days—to restore compliance with the minimum MVPHS requirement or face potential delisting from the Nasdaq Global Select Market. During this compliance period, Trinity Biotech's American Depositary Shares (ADSs) will continue trading under the ticker symbol 'TRIB' without interruption.

Non-compliance notices are standard regulatory communications that provide listed companies with a defined timeframe to address deficiencies before facing more severe consequences. Trinity Biotech's management will need to implement measures to increase its publicly held share value to meet the exchange's requirements within the specified window.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 20

Related Coverage

GlobeNewswire Inc.

Apogee Therapeutics Raises $350M via Public Offering to Fuel Biotech Pipeline

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.

APGE
GlobeNewswire Inc.

Gauzy Faces Nasdaq Delisting Risk After Stock Price Falls Below $1 Minimum

Gauzy Ltd. receives Nasdaq notice of minimum bid price deficiency, given 180 days until September 2026 to restore compliance or face delisting. No immediate trading impact.

GAUZ
GlobeNewswire Inc.

Zealand Pharma Raises Capital Through Employee Warrant Exercise

Zealand Pharma raised DKK 955,071 through exercise of 10,530 employee warrants at DKK 90.70 per share, increasing total share capital to DKK 71,515,045.

ZLDPY
GlobeNewswire Inc.

Tonix Pharma to Showcase Commercial Portfolio at BIO-Europe Spring 2026

Tonix Pharmaceuticals CEO to present commercial CNS portfolio at BIO-Europe Spring 2026, showcasing TONMYA® fibromyalgia launch success with 1,500+ prescriptions since November 2025.

TNXP
Benzinga

Roche Deploys 2,176 NVIDIA GPUs in Landmark AI Factory for Drug Discovery

Roche and NVIDIA expand AI infrastructure with 2,176 on-premises GPUs across U.S. and Europe, totaling 3,500 Blackwell units to accelerate drug discovery and diagnostics.

NVDARHHBY
GlobeNewswire Inc.

Senseonics' Eversense 365 Proves Durable: Real-World Data Shows 94% Wear Rate, Strong Glucose Control

Senseonics reports real-world data from 5,059 Eversense 365 CGM users showing 93.8% wear time and strong glucose control metrics over one year.

SENS